BXY-14
BXY-14 is a TLR2 agonist and vaccine adjuvant. BXY-14 significantly downregulates the expression of intratumoral PD-L1 in mouse models. BXY-14 acts as a vaccine adjuvant to induce antibody responses. BXY-14 exhibits synergistic efficacy when combined with the anti-PD-L1 monoclonal antibody Atezolizumab (HY-P9904) in mouse models of melanoma, and prolongs overall survival. BXY-14 is applicable to research related to melanoma.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Fòrmula: C35H66O10
- Peso molecular:646.89
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
|
TLR2 |
BXY-14 (1-106 pM) acts as a potent TLR2 agonist in hTHP-1 cells, inducing TNF-α release with an EC50 of 2.2 nM[1].
BXY-14 (10-3-103 nM; 24 h) is a potent TLR2 agonist in hPBMC that induces TNF-α release with an EC50 of 0.58 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
BXY-14 (10 mg/kg; s.c.; on days 0, 14, and 28) in combination with anti-PD-L1 enhances tumor growth inhibition, prolongs survival to 100% at day 50, and reduces intratumoral PD-L1 expression in a murine B16-OVA melanoma model, while BXY-14 (20 mg/kg; s.c.; on days 0, 14, and 28) as monotherapy also suppresses tumor growth and downregulates PD-L1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (female, 6-8 weeks old, ~20 g)[1]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:s.c.; on days 0, 14, and 28
-
Result:Induced significantly stronger total IgG, IgG1, and IgG2c anti-OVA antibody titers than positive control adjuvant Diprovocim on day 42, with a marked Th1-skewed immune bias (higher Th1/Th2 index) at 10 mg/kg.
Induced robust total IgG, IgG1, and IgG2c anti-OVA antibody titers, with no significant body weight changes observed over 10 days post-immunization, indicating good tolerance at 20 mg/kg.
-
Animal Model:C57BL/6 (female, 6-8 weeks old, ~20 g, subcutaneously injected with 2×105 B16-OVA melanoma cells on day 42 post-initial immunization)[1]
-
Dosage:10 mg/kg (in combination with anti-PD-L1); 20 mg/kg (monotherapy)
-
Administration:s.c.; on days 0, 14, and 28
-
Result:Achieved stronger tumor growth inhibition than Diprovocim plus anti-PD-L1, prolonged overall survival to 100% at day 50, significantly increased tumor cell apoptosis (higher mean fluorescence intensity of TUNEL staining), and markedly downregulated intratumoral PD-L1 expression (lower integrated optical density of PD-L1 staining) at 10 mg/kg in combination with anti-PD-L1.
Potently suppressed tumor growth, prolonged survival, and downregulated intratumoral PD-L1 expression at 20 mg/kg as monotherapy.
Chemical Information
-
Peso molecular 646.89
-
Fòrmula C35H66O10
-
SMILES
O[C@@H]1[C@H]([C@@H](O[C@H]1OC[C@@H](COC(CCCCCCCCCCCC)=O)O)[C@H](O)COC(CCCCCCCCCCCC)=O)O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
BXY-14 Related Classifications
HY-181916 Related Classifications
Powered by Bioz